Laon Medi Signs Software Development and Supply Agreement with DIO Implant

Laon Medi (CEO Seok-Joong Lee), the AI healthcare subsidiary of Laon People, announced on the 21st that it has signed an agreement with DIO Implant (CEO Jong-Won Kim), a global leader in digital implant solutions, for the joint development and supply of dental software. The signing ceremony took place at Laon Medi’s headquarters in Gwacheon, Korea.

Under the agreement, the two companies will enhance the setup and functionality of orthodontic diagnostic software, develop and implement dental treatment software such as treatment simulation and ordering systems, and collaborate in diverse areas including global market entry, marketing, and licensing businesses.

Laon Medi plans to apply its AI-based digital diagnostic and treatment technologies, which have drawn significant attention in the dental field, to orthodontic treatment. Its strategy is to further advance these technologies through the clinical application of AI-powered software and the production of clear aligners.

DIO intends to integrate Laon Medi’s AI orthodontic setup software, Laon Ortho, into its aligner production workflow. By leveraging clinical data and expertise, the company aims to significantly reduce the time required for the design and manufacturing of orthodontic devices, thereby boosting both operational and production efficiency.

Laon Medi stated:

“Through our collaboration with DIO, we aim to enhance the competitiveness of domestic AI software and elevate Korea’s medical technology to a higher level. We are committed to pioneering overseas markets so that ‘K-Dental’ can become a global trend. Following the unveiling of our AI-based automatic diagnostic feature ‘One Click’ at last year’s orthodontic conference, we will showcase an advanced solution at IDS 2025, the world’s largest dental exhibition, and at SIDEX 2025, Korea’s largest dental trade show. With growing interest across the dental and medical industries, we will continue to strengthen our technological competitiveness and expand our market presence.”

Laon Medi has already secured FDA clearance for its technology, underscoring its reliability and innovation, and has raised KRW 4.8 billion (approx. USD 3.6 million) in investment to strengthen its domestic and global competitiveness. DIO, with operations in over 70 countries including the U.S., China, and India, has established a robust global network. The collaboration between the two companies is expected to create significant synergy in advancing dental software, medical technologies, and licensing opportunities in international markets.